Statin prescribing in Northern Ireland and England pre and post introduction of the quality and outcomes framework.
OBJECTIVE
The objective of this research was to examine differences in patterns of statin prescribing between Northern Ireland and England both before and after the introduction of the Quality and Outcomes Framework (QOF).


METHODS
Primary care practices in Northern Ireland and England. Method Northern Ireland practices were matched with practices in England, statin prescribing data and QOF achievement scores (for the first year post-QOF) were obtained. Crude prescribing data from matched practices were manipulated to provide a data set of Defined Daily Doses (DDDs)/1,000 patients and cost/DDD/1,000 patients for each statin drug entity covering 1 year before and after the introduction of QOF. QOF achievements were converted into percentage scores for matched practices.


METHODS
Cost per defined daily dose (DDD) per 1,000 patients.


RESULTS
Significantly less statins (DDD/1,000 patients) were dispensed in Northern Ireland compared with the matched region in England both before and after the introduction of QOF (P < 0.001). However, significantly more statins were dispensed in both regions after the introduction of QOF. As a result of the introduction of QOF, the cost/DDD/1,000 patients rose by pound13.17 in NI, but fell by pound3.76 in the matched region in England.


CONCLUSIONS
Strategies should be considered to educate prescribers on cost-effectiveness by increasing their awareness of the negative budgetary impact resulting from early adoption of new and expensive statins and by encouraging generic prescribing.
Alabbadi
Ibrahim
I
Biopharmaceutics and Clinical Pharmacy Department, Faculty of Pharmacy, University of Jordan, Amman, Jordan.
Crealey
Grainne
G
Turner
Kathryn
K
Rafferty
Therese
T
Keenan
Lynn
L
Murray
Penny
P
McElnay
James C
JC
D003363:Cost Control; D016568:Drugs, Generic / Q000627:therapeutic use; D004739:England; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy; D008297:Male; D009660:Northern Ireland; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000191:economics* / Q000639:trends*; D017064:Process Assessment, Health Care / Q000706:statistics & numerical data*; D019984:Quality Indicators, Health Care; D012107:Research Design; D013223:Statistics as Topic
D016568:Drugs, Generic; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors